Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Peptide-based trial data, complex milestone payments, and frequent equity raises make Altimmune Inc’s disclosures tough to navigate. If you have ever searched “Altimmune SEC filings explained simply,” you already know the challenge: hundreds of pages packed with technical language and biotech accounting rules.
Stock Titan solves this problem with AI-powered summaries that turn every Altimmune quarterly earnings report 10-Q filing and Altimmune annual report 10-K simplified into plain-English insights. Our platform streams Altimmune Form 4 insider transactions real-time, flags cash-burn trends, and links each note in seconds—no more digging for footnotes on clinical trial spend. Need to monitor an unexpected disclosure? Our engine pushes alerts the moment an Altimmune 8-K material events explained notice hits EDGAR.
Whether you are comparing R&D expense trajectories or tracking Altimmune executive stock transactions Form 4, you will find every document in one place. Investors often ask, “Where can I review Altimmune proxy statement executive compensation details?” or “How should I interpret an Altimmune insider trading Form 4 transactions spike before data readouts?” Our expert commentary answers these questions and more, providing Altimmune earnings report filing analysis that ties revenue forecasts to trial timelines. By understanding Altimmune SEC documents with AI, you can evaluate dilution risk, anticipate capital needs, and follow pemvidutide’s clinical progress—all without wading through dense biotech jargon.
Altimmune, Inc. (ALT) is holding a virtual 2025 Annual Meeting of Stockholders on September 25, 2025 at 8:30 a.m. Eastern accessible at https://www.cstproxy.com/altimmune/2025 using a 12-digit control number. The proxy statement presents routine governance items: election of directors, ratification of Ernst & Young (E&Y) as independent auditors for the year ending December 31, 2025, an annual advisory "say-on-pay" vote on named executive officer compensation, and authorization to adjourn the meeting.
The filing references corporate governance materials and the Company Code of Ethics available on the investor relations site and notes the Audit Committee received PCAOB-required disclosures from E&Y and recommended inclusion of audited financial statements in the 2024 Form 10-K. Named executive officers listed for 2024 include Vipin K. Garg, Ph.D. (CEO), M. Scott Harris, M.D. (CMO), and M. Scot Roberts, Ph.D. (CSO). Benefit highlights include a 401(k) Plan with a 100% match on the first 4% of participant contributions. The statement also describes director nomination processes and related-party/merger background.
Altimmune reported strong clinical topline results from its IMPACT Phase 2b MASH trial, where weekly pemvidutide produced MASH resolution rates of 59.1% (1.2 mg) and 52.1% (1.8 mg) versus 19.1% for placebo (p<0.0001 for both doses). Fibrosis improvement by conventional ITT analysis was not statistically different, but an AI-based analysis showed a larger fibrosis reduction signal (30.6% of subjects on 1.8 mg achieved ≥60% fibrosis reduction versus 8.2% on placebo, p<0.001). Pemvidutide also drove mean weight loss of 5.0% and 6.2% at 1.2 mg and 1.8 mg versus 1.0% for placebo, and safety/tolerability appeared favorable with low discontinuation rates.
On the balance sheet, cash and equivalents were $183.1M at June 30, 2025, the company drew $15.0M of a $100M term loan facility (effective interest rate 14.4%), and generated net proceeds of $72.6M from at-the-market equity offerings in the period plus an additional $12.8M raised in July. The company recorded a six-month net loss of $41.7M and has an accumulated deficit of $603.1M. A class action alleging securities law violations was filed on August 5, 2025.
Altimmune (Nasdaq: ALT) filed an 8-K reporting positive topline data from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
- MASH resolution without fibrosis worsening reached 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001).
- Histologic fibrosis improvement (31.8%/34.5% vs 25.9% placebo) was not significant, but AI analysis showed ≥60% fibrosis reduction in 30.6% at 1.8 mg vs 8.2% placebo (p<0.001).
- Mean weight loss 5.0%/6.2% vs 1.0% placebo (p<0.001); liver fat fell 58.0%/62.8% vs 16.2%.
- Safety: 0–1.2% AE-related discontinuations; no drug-related SAEs.
Slides (Ex 99.2) accompany a call on 26 Jun 2025. Forward-looking statements cite regulatory, trial and funding risks.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
